Kiniksa PharmaceuticalsKNSA
13F holders, Q1 2025 (March 31)2holders
0new positions
0sold out
$22.21avg. 13F price*
At the end of Q1 2025, 2 institutions reported holding Kiniksa Pharmaceuticals Ltd. (KNSA) in their 13F filings, unchanged from Q4 2024. 0 opened new positions and 0 sold out. The largest holders were Harbor Capital Advisors, Inc. ($1.7M) and Birchview Capital, LP ($666K).
- Company
- Kiniksa Pharmaceuticals Ltd.
- CUSIP
- G5269C101
- Latest filing quarter
- Q1 2026
History
Number of 13F holders
Total Exit/New Position Q4 2024 → Q1 2025
| Institutions | Total Value | |
|---|---|---|
| New Positions | 0 | $0 |
| Exits | 0 | $0 |
All 13F filers, Q4 2024 → Q1 2025: 6 shares bought and 20,371 shares sold, net −20,365 shares. Counts holders who added, trimmed, opened or closed a position; split-adjusted.
Ownership 2 holders
| Harbor Capital Advisors, Inc. | 0.08% | Reduce -20.8% | 77,722 | $1.7M |
| Birchview Capital, LP | 0.58% | Add +0.0% | 30,006 | $666K |
"% of holder's portfolio" is KNSA's weight in each manager's 13F, not the share of Kiniksa Pharmaceuticals Ltd. the manager owns.